Fennec Pharmaceuticals Inc. (TSE:FRX - Free Report) - Investment analysts at HC Wainwright increased their Q2 2025 earnings per share (EPS) estimates for shares of Fennec Pharmaceuticals in a report issued on Tuesday, May 20th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will post earnings per share of ($0.10) for the quarter, up from their previous forecast of ($0.14). The consensus estimate for Fennec Pharmaceuticals' current full-year earnings is $0.60 per share. HC Wainwright also issued estimates for Fennec Pharmaceuticals' Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at $0.01 EPS, FY2025 earnings at ($0.19) EPS, Q1 2026 earnings at $0.08 EPS, Q2 2026 earnings at $0.21 EPS, Q3 2026 earnings at $0.26 EPS and Q4 2026 earnings at $0.36 EPS.
Fennec Pharmaceuticals Trading Down 7.6%
Shares of FRX stock traded down C$0.85 during mid-day trading on Thursday, reaching C$10.30. 1,006 shares of the stock traded hands, compared to its average volume of 1,301. The stock's fifty day simple moving average is C$8.42 and its two-hundred day simple moving average is C$8.60. Fennec Pharmaceuticals has a 1-year low of C$5.65 and a 1-year high of C$11.50. The company has a market cap of C$198.63 million, a price-to-earnings ratio of -174.48 and a beta of 0.25. The company has a quick ratio of 10.17, a current ratio of 7.80 and a debt-to-equity ratio of -620.83.
Insider Buying and Selling
In other Fennec Pharmaceuticals news, Director Jeffrey Hackman acquired 15,000 shares of Fennec Pharmaceuticals stock in a transaction on Monday, May 19th. The stock was purchased at an average price of C$9.77 per share, for a total transaction of C$146,580.00. Also, Director Rostislav Christov Raykov sold 10,000 shares of the stock in a transaction on Friday, April 4th. The stock was sold at an average price of C$7.46, for a total value of C$74,550.00. Insiders have sold a total of 35,645 shares of company stock valued at $316,021 over the last ninety days. 16.20% of the stock is owned by company insiders.
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
See Also
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
